Utilization of Molecular and Conventional Methods for the Identification of Nontuberculous Mycobacteria Isolated from Different Water Sources
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Discovery of a Novel Mycobacterium Asiaticum PRA-Hsp65 Pattern
Infection, Genetics and Evolution 76 (2019) 104040 Contents lists available at ScienceDirect Infection, Genetics and Evolution journal homepage: www.elsevier.com/locate/meegid Short communication Discovery of a novel Mycobacterium asiaticum PRA-hsp65 pattern T ⁎ William Marco Vicente da Silva , Mayara Henrique Duarte, Luciana Distásio de Carvalho, Paulo Cesar de Souza Caldas, Carlos Eduardo Dias Campos, Paulo Redner, Jesus Pais Ramos National Reference Laboratory for Tuberculosis, Centro de Referência Professor Hélio Fraga, Escola Nacional de Saúde Pública, Fiocruz, RJ, Brazil ARTICLE INFO ABSTRACT Keywords: Twenty-one pulmonary sputum samples from nine Brazilian patients were analyzed by the PRA-hsp65 method PRA-hsp65 for identification of Mycobacterium species and the results were compared by sequencing. We reported a mu- Identification tation at the position 381, that generates a suppression cutting site in the BstEII enzyme, thus leading to a new M. asiaticum PRA-hsp65 pattern for M. asiaticum identification. Nontuberculous mycobacteria (NTM) are opportunistic human pa- widely used for identification of Mycobacterium species. The PRA-hsp65 thogens. NTM are widespread in nature and are found in environmental methodology consists of restriction analysis of a 441 bp PCR fragment sources, including water, soil, and aerosols. They are resistant to most of the hsp65 gene with enzymes BstEII and HaeIII (Campos et al., 2012; disinfectants, including those used in treated water. More than 170 Devulder, 2005; Tamura et al., 2011; Verma et al., 2017). Nowadays, NTM species have been described (http://www.bacterio.net/ M. asiaticum has a single pattern described as type 1 in the PRAsite mycobacterium.html), however, the knowledge about NTM infections database (http://app.chuv.ch/prasite/index.html) based on the fol- is still limited (Chin'ombe et al., 2016; Tortoli, 2014). -
Numerical Analysis of Rapidly Growing, Scotochromogenic Mycobacteria, Including Mycobacterium O Buense Sp
INTERNATIONALJOURNAL OF SYSTEMATICBACTERIOLOGY, July 1981, p. 263-275 Vol. 31, No. 3 0020-7713/81/030263-13$02.00/0 Numerical Analysis of Rapidly Growing, Scotochromogenic Mycobacteria, Including Mycobacterium o buense sp. nov., norn. rev., Mycobacterium rhodesiae sp. nov., nom. rev., Mycobacterium aichiense sp. nov., norn. rev., Mycobacterium chubuense sp. nov., norn. rev., and Mycobacterium tokaiense sp. nov., nom. rev. MICHIO TSUKAMURA, SHOJI MIZUNO, AND SUM10 TSUKAMURA The National Chubu Hospital, Obu, Aichi, Japan 474 We performed numerical analyses of 155 strains of rapidly growing, scotochrom- ogenic mycobacteria by two different methods; in one method we used 104 characters, and in the other we used 84 characters. The following taxa appeared as distinct clusters: Myco bacterium thermoresistibile, Myco bacterium flavescens, Mycobacterium duvalii, Mycobacterium phlei, “Mycobacterium o buense,” My- co bacterium parafortuitum, Mycobacterium vaccae, Mycobacterium sphagni, “Mycobacterium aichiense,” “Mycobacterium rhodesiae,” Mycobacterium neoaurum, “Mycobacterium chubuense,” “Mycobacterium tokaiense,” and My- cobacterzum komossense (names in quotation marks are not on the Approved Lists of Bacterial Names). M. flavescens strains were divided into two subgroups, one consisting of strains isolated in Japan and the other consisting of strains isolated in Rhodesia and strains received from the American Type Culture Collection, including the type strain of M. flavescens (ATCC 14474). We found that there are many species of rapidly growing, scotochromogenic mycobacteria, and we believe that new species should be recognized and named on the basis of at least three strains. The following species appeared to be distinct from all presently named species: “Mycobacteriumgallinarum,” “Mycobacterium armen- tun,” “Mycobacterium pelpallidurn,” and “Mycobacterium taurus.” However, each of these species was proposed on the basis of only one or two strains. -
Role of Immunotherapy in the Treatment of Tuberculosis
ROLE OF IMMUNOTHERAPY IN THE TREATMENT OF TUBERCULOSIS MURTHY, K.J.R. VIJAYA LAKSHMI, V. and Singh, S. Bhagwan Mahavir Medical Research Centre, 10-1-1, Mahavir Marg, Hyderabad - 500 029. India. ABSTRACT Tuberculosis is caused by Mycobacterium tuberculosis, an intracellular pathogen residing in macrophages. Cell mediated immune (CMI) and delayed type of hypersensitive (DTH) responses play a pivotal role in providing protection to the host. The most important cell is the CD4 T lymphocyte, which is divided into TH1 and TH2 subsets depending on the type of cytokines produced. TH1 cells produce the cytokines interferon-gamma and interleukin-2, which are important for activa- tion of antimycobacterial activities and essential for the DTH response. Grange opines that the immune response in an individual with tuberculous infection gets locked in' to one or other pattern of response viz. TH1 or TH2 response, the latter response leading to tissue damage and progression of disease. Stanford and co-workers conducted several studies on the effectiveness of Mycobacterium vaccae, as an immunotherapeutic agent for tuberculosis. It is non-pathogenic in humans and is thought to be a powerful TH1 adjuvant. A series of small studies pointed that M. vaccae has a beneficial effect and there is enough evidence now to show that its use as an immunotherapeutic agent, as an adjunct to chemotherapy in the treatment of tuberculosis especially at a time when drug resistance is rampant, appears promising. KEY WORDS : Tuberculosis, Drug-Resistance, Immunotherapy, T Cell Responses. ROLE OF IMMUNOTHERAPY IN THE cytokines secreted by the TH1 cell are interferon- TREATMENT OF TUBERCULOSIS gamma (IFN-~,) and interleukin-2 (IL-2). -
Mycobacterium Arupense Among the Isolates of Non-Tuberculous Mycobacteria from Human, Animal and Environmental Samples
Veterinarni Medicina, 55, 2010 (8): 369–376 Original Paper Mycobacterium arupense among the isolates of non-tuberculous mycobacteria from human, animal and environmental samples M. Slany1, J. Svobodova2, A. Ettlova3, I. Slana1, V. Mrlik1, I. Pavlik1 1Veterinary Research Institute, Brno, Czech Republic 2Regional Institute of Public Health, Brno, Czech Republic 3BioPlus, s.r.o., Brno, Czech Republic ABSTRACT: Mycobacterium arupense is a non-tuberculous, potentially pathogenic species rarely isolated from humans. The aim of the study was to ascertain the spectrum of non-tuberculous mycobacteria within 271 sequenced mycobacterial isolates not belonging to M. tuberculosis and M. avium complexes. Isolates were collected between 2004 and 2009 in the Czech Republic and were examined within the framework of ecological studies carried out in animal populations infected with mycobacteria. A total of thirty-three mycobacterial species were identified. This report describes the isolation of M. arupense from the sputum of three human patients and seven different animal and environmental samples collected in the last six years in the Czech Republic: one isolate from leftover refrigerated organic dog food, two isolates from urine and clay collected from an okapi (Okapia johnstoni) and antelope bongo (Tragelaphus eurycerus) enclosure in a zoological garden, one isolate from the soil in an eagle’s nest (Haliaeetus albicilla) band two isolates from two common vole (Microtus arvalis) livers from one cattle farm. All isolates were identified by biochemical tests, morphology and 16S rDNA sequencing. Also, retrospective screening for M. arupense occurrence within the collected isolates is presented. Keywords: 16S rDNA sequencing; non-tuberculous mycobacteria; ecology Non-tuberculous mycobacteria (NTM) are ubiq- According to the commonly used Runyon clas- uitous in the environment and are responsible for sification scheme, NTM are categorized by growth several diseases in humans and/or animals known rate and pigmentation. -
Immunotherapy of TB…
Results from Phase III, placebo-controlled, 2:1 randomized, double-blind trial of tableted TB vaccine (V7) containing 10 μg of heat-killed Mycobacterium vaccae administered daily for one month Correspondence: Aldar Bourinbaiar * Tel: +976 95130306; +1 301 476-0930 * e-mail: [email protected] Tuberculosis • 33% of people carry TB bacteria = 2.5 billion • Every second, a person becomes ill with TB • Every year 10 mln people develop TB and 2 mln die • Drug-resistant TB poised to become global pandemic • Less than 3% of drug-resistant TB is treated today Th-1 cells = IFN-ɣ, IL-2, GM-CSF, IFN-ɑ, TNF-ɑ, IL-12, IL-18 Th-2 cells = IL-4, IL-5, IL-13 Th-17 cells = IL-6, IL-17, IL-22, TNF-ɑ Treg cells = IL-10, TGF-ɓ B cells = IFN-ɑ, IL-1ɓ, IL-12 Monocytes = IL-8, IL-18, TNF-ɑ State-of-the-art: immunology of TB – a great deal of information gathered but… can't see the forest through the trees When this vast knowledge was applied to immunotherapy of TB…. it failed… It also resulted in negative attitude toward immunotherapy • IL-2 (increased bacterial load) • IL-12 (no effect) • GM-CSF (clearance not confirmed) • IFN-ɣ (irreproducible, no effect) • IFN-ɑ (negative outcome) • anti-TNF-ɑ (negative outcome) • Thalidomide (negative outcome) • Corticosteroids (irreproducible, negative effect) Paradoxes of Tuberculosis • 1/3 of world population (~2.5bln) have latent M. tuberculosis • Yet only about 10 Million people (0.004%) develop TB • M. tuberculosis is in symbiotic relationship with the host • In some cases it’s even beneficial (asthma, cancer) • M. -
Brief Communication
BRIEF COMMUNICATION http://dx.doi.org/10.1590/S1678-9946201860006 Nontuberculous mycobacteria in milk from positive cows in the intradermal comparative cervical tuberculin test: implications for human tuberculosis infections Carmen Alicia Daza Bolaños1, Marília Masello Junqueira Franco1, Antonio Francisco Souza Filho2, Cássia Yumi Ikuta2, Edith Mariela Burbano-Rosero3, José Soares Ferreira Neto2, Marcos Bryan Heinemann2, Rodrigo Garcia Motta4, Carolina Lechinski de Paula1, Amanda Bonalume Cordeiro de Morais1, Simony Trevizan Guerra1, Ana Carolina Alves1, Fernando José Paganini Listoni1, Márcio Garcia Ribeiro1 ABSTRACT Although the tuberculin test represents the main in vivo diagnostic method used in the control and eradication of bovine tuberculosis, few studies have focused on the identification of mycobacteria in the milk from cows positive to the tuberculin test. The aim of this study was to identify Mycobacterium species in milk samples from cows positive to the comparative intradermal test. Milk samples from 142 cows positive to the comparative intradermal test carried out in 4,766 animals were aseptically collected, cultivated on Lowenstein-Jensen and Stonebrink media and incubated for up to 90 days. Colonies compatible with mycobacteria were stained by Ziehl-Neelsen to detect acid-fast bacilli, while to confirm the Mycobacterium genus, conventional PCR was performed. Fourteen mycobacterial strains were isolated from 12 cows (8.4%). The hsp65 gene sequencing identified M. engbaekii (n=5), M. arupense 1Universidade Estadual Paulista, -
The Crystal Structure of Rv2991 from Mycobacterium Tuberculosis : an F 420 Binding Protein with Unknown Function
This is a repository copy of The crystal structure of Rv2991 from Mycobacterium tuberculosis : An F 420 binding protein with unknown function. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/147627/ Version: Accepted Version Article: Benini, Stefano, Haouz, Ahmed, Proux, Florence et al. (2 more authors) (2019) The crystal structure of Rv2991 from Mycobacterium tuberculosis : An F 420 binding protein with unknown function. JOURNAL OF STRUCTURAL BIOLOGY. pp. 216-224. ISSN 1047-8477 https://doi.org/10.1016/j.jsb.2019.03.006 Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ The crystal structure of Rv2991 from Mycobacterium tuberculosis: An F420 binding protein with unknown function Stefano Beninia, ⁎ [email protected] Ahmed Haouzb Florence Prouxb, 1 Pedro Alzaric Keith Wilsond a Bioorganic Chemistry and Bio-Crystallography Laboratory (B2Cl), Faculty of Science and Technology, Free University of Bolzano, Piazza Università 5, Bolzano 39100, Italy bC2RT-Plateforme de cristallographie, Institut Pasteur, CNRS UMR 3528, 75724 Paris Cedex 15, France cUnité de Microbiologie Structurale, Institut Pasteur, CNRS UMR 3528, Université Paris Diderot, Sorbonne Paris Cité, 75724 Paris Cedex 15, France d York Structural Biology Laboratory, Department of Chemistry, University of York, Heslington, York YO10 5DD, UK ⁎Corresponding author. -
Heat-Killed M. Aurum Aogashima (Brand Name: Au+) Novel Food Ingredient Application
Page 1 of 27 Heat-killed M. aurum Aogashima (Brand name: Au+) Novel food Ingredient Application By Solution Sciences Ltd. Page 2 of 27 1. Contents Table 1: Abbreviations ........................................................................................................................................ 3 Table 2: List of Annexes ...................................................................................................................................... 4 Table 3: List of References .................................................................................................................................. 5 1. Administrative Data .................................................................................................................................... 8 Notes on confidentiality .................................................................................................................................. 8 2. General Introduction and Description of Mycobacterium aurum Aogashima ............................................ 9 I The purpose of tHe novel food ingredient .............................................................................................. 9 3. Identification of essential information requirements ............................................................................... 11 4. Consultation of structured schemes ......................................................................................................... 12 I Structured ScHeme I: Specification of tHe Novel Food ingredient -
View of Results 1SGN the Overall Results of the Two Methods Are Summarized in M
BMC Microbiology BioMed Central Research article Open Access Reliable identification of mycobacterial species by PCR-restriction enzyme analysis (PRA)-hsp65 in a reference laboratory and elaboration of a sequence-based extended algorithm of PRA-hsp65 patterns Erica Chimara1, Lucilaine Ferrazoli1, Suely Yoko Misuka Ueky1, Maria Conceição Martins1, Alan Mitchel Durham2, Robert D Arbeit3 and Sylvia Cardoso Leão*4 Address: 1Instituto Adolfo Lutz, São Paulo, Brazil, 2Instituto de Matemática e Estatística, Universidade de São Paulo, São Paulo, Brazil, 3Tufts University School of Medicine, Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts, USA and 4Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo, São Paulo, Brazil Email: Erica Chimara - [email protected]; Lucilaine Ferrazoli - [email protected]; Suely Yoko Misuka Ueky - [email protected]; Maria Conceição Martins - [email protected]; Alan Mitchel Durham - [email protected]; Robert D Arbeit - [email protected]; Sylvia Cardoso Leão* - [email protected] * Corresponding author Published: 20 March 2008 Received: 17 October 2007 Accepted: 20 March 2008 BMC Microbiology 2008, 8:48 doi:10.1186/1471-2180-8-48 This article is available from: http://www.biomedcentral.com/1471-2180/8/48 © 2008 Chimara et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Identification of nontuberculous mycobacteria (NTM) based on phenotypic tests is time-consuming, labor-intensive, expensive and often provides erroneous or inconclusive results. -
Mycobacterium Vaccae Has Been Given to Patients with Prostate Cancer and Melanoma Indicating a Possible Beneficial Effect on Disease Activity in Such Patients
British Journal of Cancer (2000) 83(7), 853–857 © 2000 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1401, available online at http://www.idealibrary.com on A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma MER O’Brien1,2, A Saini1, IE Smith1, A Webb1, K Gregory1, R Mendes1,3, C Ryan2, K Priest1, KV Bromelow3, RD Palmer4, N Tuckwell6, DA Kennard5 and BE Souberbielle1,3 1Royal Marsden Hospital NHS Trust, Sutton, Surrey, SM2 5PT; 2Kent Cancer Centre, Maidstone, ME16 9QQ; 3Dept of Molecular Medicine, King’s College, SE5 9NU, London, 4Department of Bacteriology, University College London Medical School, W1P 6DB; 5SR Pharma, 26th Floor, Centre Point, 103 New Oxford Street, London WC1A 1DD, UK Summary Mycobacterial preparations have been used with limited success against cancer apart from superficial bladder cancer. Recently, a therapeutic vaccine derived from Mycobacterium vaccae has been given to patients with prostate cancer and melanoma indicating a possible beneficial effect on disease activity in such patients. We have recently initiated a series of randomized studies to test the feasibility and toxicity of combining a preparation of heat-killed Mycobacterium vaccae (designated SRL172) with a multidrug chemotherapy regimen to treat patients with inoperable non-small cell lung cancer (NSCLC) and mesothelioma. 28 evaluable patients with previously untreated symptomatic NSCLC and mesothelioma were randomized to receive either 3 weekly intravenous combination chemotherapy alone, or chemotherapy given with monthly intra-dermal injections of SRL172. Safety and tolerability were scored by common toxicity criteria and efficacy was evaluated by survival of patients and by tumour response assessed by CT scanning. -
Mycobacterium Austroafricanum Sp
INTERNATIONALJOURNAL OF SYSTEMATICBACTERIOLOGY, July 1983, p. 460-469 Vol. 33, No. 3 0020-7713/83/030460-10$02.00/0 Copyright 0 1983, International Union of Microbiological Societies Numerical Taxonomy of Rapidly Growing, Scotochromogenic Mycobacteria of the Mycobacterium parafortuitum Complex: Mycobacterium austroafricanum sp. nov. and Mycobacterium diernhoferi sp. nov., nom. rev. MICHIO TSUKAMURA,’* HERMINA J. VAN DER MEULEN,2 AND WILHELM 0. K. GRABOW3 National Chubu Hospital, Obu, Aichi, Japan 474l: South African Institute for Medical Research, Johannesburg 2001, South Africa2; and National Institute for Water Research, Pretoria 0002, South Africa3 A numerical analysis of phenetic data collected from rapidly growing, scotoch- romogenic mycobacterial strains isolated from water in South Africa and from strains of the taxa Mycobacterium parafortuitum, Mycobacterium aurum, Myco- bacterium neoaurum, and “Mycobacterium diernhoferi” indicated that all of these organisms belong to the Mycobacterium parqfortuitum complex. Our results also indicated that each of the taxa mentioned above is worthy of species status within the complex. The name Mycobacterium austroafricanum sp. nov. is proposed for the South African isolates, and the characteristics of these isolates are described; the type strain is E9789-SA12441 (= ATCC 33464). The name Mycobacterium diernhoferi is revived for the organism described originally by Bonicke and Juhasz in 1965; the type strain of this species is strain 41001 (= ATCC 19340). Three species of rapidly growing, scotochro- at -20°C and were subcultured at 6-month intervals. mogenic mycobacteria, Mycobacterium para- Only the strains deposited in the American Type fortuitum (i6), Mycobacte&m aurum (7), and Culture Collection, Rockville, Md., are shown in Mycobacteriurn neoaurum (9), have not been Table 1. -
Nontuberculous Mycobacteria in Respiratory Samples from Patients with Pulmonary Tuberculosis in the State of Rondônia, Brazil
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 108(4): 457-462, June 2013 457 Nontuberculous mycobacteria in respiratory samples from patients with pulmonary tuberculosis in the state of Rondônia, Brazil Cleoni Alves Mendes de Lima1,2/+, Harrison Magdinier Gomes3, Maraníbia Aparecida Cardoso Oelemann3, Jesus Pais Ramos4, Paulo Cezar Caldas4, Carlos Eduardo Dias Campos4, Márcia Aparecida da Silva Pereira3, Fátima Fandinho Onofre Montes4, Maria do Socorro Calixto de Oliveira1, Philip Noel Suffys3, Maria Manuela da Fonseca Moura1 1Centro Interdepartamental de Biologia Experimental e Biotecnologia, Universidade Federal de Rondônia, Porto Velho, RO, Brasil 2Laboratório Central de Saúde Pública de Rondônia, Porto Velho, RO, Brasil 3Laboratório de Biologia Molecular Aplicada a Micobactérias, Instituto Oswaldo Cruz 4Centro de Referência Professor Hélio Fraga, Escola Nacional de Saúde Pública-Fiocruz, Rio de Janeiro, RJ, Brasil The main cause of pulmonary tuberculosis (TB) is infection with Mycobacterium tuberculosis (MTB). We aimed to evaluate the contribution of nontuberculous mycobacteria (NTM) to pulmonary disease in patients from the state of Rondônia using respiratory samples and epidemiological data from TB cases. Mycobacterium isolates were identified using a combination of conventional tests, polymerase chain reaction-based restriction enzyme analysis of hsp65 gene and hsp65 gene sequencing. Among the 1,812 cases suspected of having pulmonary TB, 444 yielded bacterial cultures, including 369 cases positive for MTB and 75 cases positive for NTM. Within the latter group, 14 species were identified as Mycobacterium abscessus, Mycobacterium avium, Mycobacterium fortuitum, Myco- bacterium intracellulare, Mycobacterium gilvum, Mycobacterium gordonae, Mycobacterium asiaticum, Mycobac- terium tusciae, Mycobacterium porcinum, Mycobacterium novocastrense, Mycobacterium simiae, Mycobacterium szulgai, Mycobacterium phlei and Mycobacterium holsaticum and 13 isolates could not be identified at the species level.